The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Neutrophil-lymphocyte ratio (NLR) as a predictive biomarker for response to high dose interleukin 2 (HDIL-2) in patients with metastatic renal cell carcinoma (mRCC).
 
James Arthur Kuzman
No Relationships to Disclose
 
David D. Stenehjem
No Relationships to Disclose
 
Shiven B. Patel
No Relationships to Disclose
 
Joseph Merriman
No Relationships to Disclose
 
David Michael Gill
No Relationships to Disclose
 
Andrew Hahn
No Relationships to Disclose
 
Archana M. Agarwal
No Relationships to Disclose
 
Sumati Gupta
Stock and Other Ownership Interests - Salarius Pharmaceuticals (I)
Consulting or Advisory Role - Keryx (I)
Research Funding - Hydrocephalus Clinical Research Network (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Viralytics (Inst)
Travel, Accommodations, Expenses - Keryx (I)
 
Dan Albertson
No Relationships to Disclose
 
Anitha Alex
No Relationships to Disclose
 
Neeraj Agarwal
Research Funding - amgen (Inst); Bayer (Inst); BN ImmunoTherapeutics (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); ImClone Systems (Inst); Medivation (Inst); Novartis (Inst); Pfizer (Inst); Rexahn Pharmaceuticals (Inst); Takeda (Inst); TRACON Pharma (Inst)